TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter,Double Blind,Controlled With Placebo Trial About Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Liver Cirrhosis and Variceal Bleeding
Brief Summary: This is a prospective, double blind controlled trial in which patients with esophagic variceal bleeding treated with standard therapy (endoscopic variceal ligation(EVL) + B-blockers), will be randomized to receive statins or placebo. They will be followed up during 12 months to determinate whether statins are effective in prevention of variceal bleeding recurrence and evaluate patient survival.

Randomization will be stratified according to the degree of hepatic insufficiency, assessed by the Child-Pugh classifications (A,B or C).


Options:
A: Arm Label: Standard therapy + Simvastatin; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: Standard therapy + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): Standard therapy + Simvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Standard therapy + placebo
B: Arm Label: Ligation and Cyanoacrylate Group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Ligation and Cyanoacrylate | Arm Label: Ligation plus Sclerotherapy and Cyanoacrylate Group; Type: EXPERIMENTAL; Interventions: Procedure: Ligation plus Sclerotherapy and Cyanoacrylate Group | Intervention Type: PROCEDURE; Name: Ligation and Cyanoacrylate; Assigned to Arm(s): Ligation and Cyanoacrylate Group | Intervention Type: PROCEDURE; Name: Ligation plus Sclerotherapy and Cyanoacrylate Group; Assigned to Arm(s): Ligation plus Sclerotherapy and Cyanoacrylate Group
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Other: Emergency TIPS | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: OTHER; Name: Emergency TIPS; Assigned to Arm(s): B
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency portacaval shunt | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Emergency and long-term endoscopic sclerotherapy | Intervention Type: PROCEDURE; Name: Emergency portacaval shunt; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Emergency and long-term endoscopic sclerotherapy; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Study of Two Different Doses of the Subcutaneous Administration of an Immunotherapeutic Vaccine, DPX-0907 in Advanced Stage Patients With Ovarian, Breast or Prostate Cancer
Brief Summary: To determine the safety and immunogenicity profile of two (2) different doses of the vaccine DPX-0907 to treat breast, ovarian and prostate cancer.


Options:
A: Arm Label: 0.25ml dose DPX-0907; Type: EXPERIMENTAL; Interventions: Biological: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG | Arm Label: 1ml dose DPX-0907; Type: EXPERIMENTAL; Interventions: Biological: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG | Intervention Type: BIOLOGICAL; Name: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG; Assigned to Arm(s): 0.25ml dose DPX-0907, 1ml dose DPX-0907
B: Intervention Type: BIOLOGICAL; Name: CDX-1401 in combination with Resiquimod and/or Poly-ICLC; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: CDX-1401; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: Resiquimod; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: poly-ICLC; Assigned to Arm(s): N/A
C: Intervention Type: BIOLOGICAL; Name: anti-EpCAM x anti-CD3 (removab); Assigned to Arm(s): N/A
D: Arm Label: Non-randomized Cvac; Type: EXPERIMENTAL; Interventions: Biological: Cvac | Arm Label: Randomized Cvac; Type: EXPERIMENTAL; Interventions: Biological: Cvac | Arm Label: Observational standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Cvac; Assigned to Arm(s): Non-randomized Cvac, Randomized Cvac

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Interest of Angiotensin-converting Enzyme Inhibitors on Early Sickle Cell Renal Disease in Children. A Randomized, Double-blind Trial Enalapril vs Placebo.
Brief Summary: Patients with sickle cell anaemia may develop renal disease. In fact, renal disease occurred in 40% of adults patients (macroalbuminuria) with evolution to end-stage renal disease for half of them. Microalbuminuria is an early and sensitive marker of glomerular damage. It appears during the first decade and occurred in 20 to 25% of infants (2 to 18 years). Physiopathology of renal scarring is not well understood actually. Renal scarring might be due to glomerular hyperfiltration and vascular and endothelial damage. Angiotensin-converting enzyme inhibitors (ACE) were studied and used in diabetic nephropathy. In a study on 26 sickle cell adults, albuminuria was reduced about 50% by ACE compared to placebo after six months treatment. It might be interesting studying ACE efficacy in sickle cell children with microalbuminuria because renal disease is directly related to sickle cell and is not influenced by other cardiovascular risk factors like in adult patients.

We hypothesized to have a successful ACE treatment in more than 40% of cases after a nine months treatment period. A success is defined as a 50% reduction of the albuminuria/creatinuria ratio.


Options:
A: Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Enalapril | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Enalapril; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enalapril | Arm Label: N-Acetylcysteine; Type: ACTIVE_COMPARATOR; Interventions: Drug: N-Acetylcysteine | Intervention Type: DRUG; Name: Enalapril; Assigned to Arm(s): Enalapril | Intervention Type: DRUG; Name: N-Acetylcysteine; Assigned to Arm(s): N-Acetylcysteine
C: Arm Label: Patients With Prior Hydroxyurea; Type: N/A; Interventions: N/A | Arm Label: Patients Without Prior Hydroxyurea; Type: N/A; Interventions: N/A
D: Arm Label: Hydroxyurea; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydroxyurea | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydroxyurea; Assigned to Arm(s): Hydroxyurea | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acupuncture in Chronic Migraine: A Randomized Controlled Trial
Brief Summary: The aim of this study was to investigate the efficacy and tolerance of acupuncture treatment compared with pharmacologic treatment in patients with chronic migraines.Besides, the investigators tested whether the clinical effects of acupuncture in chronic migraine prophylaxis are mediated by changes of the plasma CGRP (Calcitonin gene-related peptide).


Options:
A: Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): N/A
B: Arm Label: acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: acupuncture | Arm Label: topiramate; Type: ACTIVE_COMPARATOR; Interventions: Drug: topiramate | Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): acupuncture | Intervention Type: DRUG; Name: topiramate; Assigned to Arm(s): topiramate
C: Arm Label: group 1; Type: EXPERIMENTAL; Interventions: Other: acupuncture | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Other: acupuncture | Arm Label: group 3; Type: EXPERIMENTAL; Interventions: Other: acupuncture | Arm Label: group 4; Type: SHAM_COMPARATOR; Interventions: Other: acupuncture | Intervention Type: OTHER; Name: acupuncture; Assigned to Arm(s): Group 2, group 1, group 3, group 4
D: Arm Label: acupoint-meridian group; Type: EXPERIMENTAL; Interventions: Other: acupuncture | Arm Label: sham-acupoint group; Type: OTHER; Interventions: Other: acupuncture | Arm Label: waiting list; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: acupuncture; Assigned to Arm(s): acupoint-meridian group, sham-acupoint group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chiropractic and Exercise for Low Back Pain in Adolescents
Brief Summary: Recent research has confirmed that low back pain (LBP) is a significant health problem not only for adults, but also for children and adolescents. Given the enormous social and economic costs associated with LBP, it is critical that attempts be made to decrease the burden of LBP for patients and society.

The primary aim of this project is to determine the relative clinical effectiveness of 3 months of chiropractic care and supervised exercise versus supervised exercise in 184 adolescents with sub-acute recurrent, or chronic LBP. Relative effectiveness will be evaluated in the short, intermediate and long term using pain as the primary outcome measure. Secondary aims are to assess group differences in patient self-reported disability, quality of life, perceived improvement, satisfaction, activity levels, lumbar dynamic motion, and trunk muscle endurance. Patients' and caregivers' perceptions of treatment using qualitative interviews will also be assessed.


Options:
A: Arm Label: Internet-based JIA Self-Management Program; Type: EXPERIMENTAL; Interventions: Behavioral: Teens Taking Charge | Arm Label: Attention Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Management | Intervention Type: BEHAVIORAL; Name: Teens Taking Charge; Assigned to Arm(s): Internet-based JIA Self-Management Program | Intervention Type: BEHAVIORAL; Name: Self-Management; Assigned to Arm(s): Attention Control Group
B: Arm Label: Chiropractic + Exercise; Type: EXPERIMENTAL; Interventions: Other: Chiropractic + Exercise | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Chiropractic + Exercise; Assigned to Arm(s): Chiropractic + Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: Treatment with manipulation; Type: EXPERIMENTAL; Interventions: Procedure: Advice and exercise-based treatment plus joint manipulation | Arm Label: Treatment without manipulation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Advice and exercise-based treatment | Intervention Type: PROCEDURE; Name: Advice and exercise-based treatment plus joint manipulation; Assigned to Arm(s): Treatment with manipulation | Intervention Type: PROCEDURE; Name: Advice and exercise-based treatment; Assigned to Arm(s): Treatment without manipulation
D: Intervention Type: BEHAVIORAL; Name: Aerobic and Qi gong Exercise; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chiropractic and Exercise for Low Back Pain in Adolescents
Brief Summary: Recent research has confirmed that low back pain (LBP) is a significant health problem not only for adults, but also for children and adolescents. Given the enormous social and economic costs associated with LBP, it is critical that attempts be made to decrease the burden of LBP for patients and society.

The primary aim of this project is to determine the relative clinical effectiveness of 3 months of chiropractic care and supervised exercise versus supervised exercise in 184 adolescents with sub-acute recurrent, or chronic LBP. Relative effectiveness will be evaluated in the short, intermediate and long term using pain as the primary outcome measure. Secondary aims are to assess group differences in patient self-reported disability, quality of life, perceived improvement, satisfaction, activity levels, lumbar dynamic motion, and trunk muscle endurance. Patients' and caregivers' perceptions of treatment using qualitative interviews will also be assessed.


Options:
A: Arm Label: Mindfulness Group; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Group | Intervention Type: BEHAVIORAL; Name: Mindfulness Group; Assigned to Arm(s): Mindfulness Group
B: Arm Label: Behavioural Intervention/Feedback; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Arm Label: Video Attention Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Video Attention Control | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Behavioural Intervention/Feedback | Intervention Type: OTHER; Name: Video Attention Control; Assigned to Arm(s): Video Attention Control
C: Arm Label: Multimodal Rehabilitation Program; Type: EXPERIMENTAL; Interventions: Behavioral: Multimodal Rehabilitation Program | Arm Label: Care as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Care as Usual | Intervention Type: BEHAVIORAL; Name: Multimodal Rehabilitation Program; Assigned to Arm(s): Multimodal Rehabilitation Program | Intervention Type: BEHAVIORAL; Name: Care as Usual; Assigned to Arm(s): Care as Usual
D: Arm Label: Chiropractic + Exercise; Type: EXPERIMENTAL; Interventions: Other: Chiropractic + Exercise | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Exercise | Intervention Type: OTHER; Name: Chiropractic + Exercise; Assigned to Arm(s): Chiropractic + Exercise | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of the Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary ByPass Surgery; A Randomized Controlled Trial
Brief Summary: Experimental data have demonstrated favourable effects of statins on endothelial progenitor cell (EPC) mobilization from the bone marrow, and cardiac homing. The purpose of the present prospective randomized controlled trial is to determine the effects of aggressive atorvastatin treatment (40 mg daily 2-weeks prior to surgery) on the number of endothelial progenitor cells (EPCs) after cardiopulmonary bypass by comparing with placebo.


Options:
A: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ulinastatin; Type: EXPERIMENTAL; Interventions: Drug: Ulinastatin | Arm Label: Tranexamic Acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline Solution | Intervention Type: DRUG; Name: Ulinastatin; Assigned to Arm(s): Ulinastatin | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Saline Solution; Assigned to Arm(s): Placebo
C: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment
D: Arm Label: Dexamethasone; Type: EXPERIMENTAL; Interventions: Drug: Dexamethasone | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Dexamethasone; Assigned to Arm(s): Dexamethasone | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of the Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary ByPass Surgery; A Randomized Controlled Trial
Brief Summary: Experimental data have demonstrated favourable effects of statins on endothelial progenitor cell (EPC) mobilization from the bone marrow, and cardiac homing. The purpose of the present prospective randomized controlled trial is to determine the effects of aggressive atorvastatin treatment (40 mg daily 2-weeks prior to surgery) on the number of endothelial progenitor cells (EPCs) after cardiopulmonary bypass by comparing with placebo.


Options:
A: Arm Label: treatment; Type: EXPERIMENTAL; Interventions: Drug: Simvastatin | Arm Label: untreated; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): treatment
B: Arm Label: Atorvastatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: CRESTOR; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: n-3 PUFA | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Rosuvastatin | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: n-3 PUFA; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Long Term Physical Training Once a Week on Fitness and Quality of Life in Elderly Asthmatics
Brief Summary: This controlled study is undertaken to investigate the effects of a long term outpatient training program on physical fitness and quality of life in elderly asthmatics.


Options:
A: Arm Label: Exercise, dietary and behavioral therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary, Behavioral: Education Program, Behavioral: Behavioral Therapy, Other: Exercise Training | Arm Label: Dietary and behavioral therapy; Type: SHAM_COMPARATOR; Interventions: Behavioral: Dietary, Behavioral: Education Program, Behavioral: Behavioral Therapy, Other: Stretching and Breathing exercise | Intervention Type: BEHAVIORAL; Name: Dietary; Assigned to Arm(s): Dietary and behavioral therapy, Exercise, dietary and behavioral therapy | Intervention Type: BEHAVIORAL; Name: Education Program; Assigned to Arm(s): Dietary and behavioral therapy, Exercise, dietary and behavioral therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Therapy; Assigned to Arm(s): Dietary and behavioral therapy, Exercise, dietary and behavioral therapy | Intervention Type: OTHER; Name: Exercise Training; Assigned to Arm(s): Exercise, dietary and behavioral therapy | Intervention Type: OTHER; Name: Stretching and Breathing exercise; Assigned to Arm(s): Dietary and behavioral therapy
B: Arm Label: Exercise training; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Exercise training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Exercise training; Assigned to Arm(s): Exercise training
C: Arm Label: Aerobic exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic exercise | Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Usual care | Intervention Type: BEHAVIORAL; Name: Aerobic exercise; Assigned to Arm(s): Aerobic exercise | Intervention Type: BEHAVIORAL; Name: Usual care; Assigned to Arm(s): Usual care
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention; Assigned to Arm(s): Lifestyle intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of MK-4305 in Patients With Primary Insomnia - Study A
Brief Summary: This is a multicenter study to test the hypothesis that suvorexant (MK-4305) is superior to placebo in improving insomnia as measured by change from baseline in: subjective total sleep time and time to sleep onset, wake time after persistent sleep onset, and latency to onset of persistent sleep. Participants who complete the initial 3-month Treatment (TRT) Phase may participate in an optional 3-month Extension (EXT) Phase.


Options:
A: Arm Label: Suvorexant HD; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant High Dose (HD) | Arm Label: Suvorexant LD; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant Low Dose (LD) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: Suvorexant High Dose (HD); Assigned to Arm(s): Suvorexant HD | Intervention Type: DRUG; Name: Suvorexant Low Dose (LD); Assigned to Arm(s): Suvorexant LD | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant, Drug: Dose-matched Placebo to Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dose-matched Placebo to Suvorexant | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Dose-matched Placebo to Suvorexant; Assigned to Arm(s): Placebo, Suvorexant
D: Arm Label: Suvorexant; Type: EXPERIMENTAL; Interventions: Drug: Suvorexant | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Suvorexant; Assigned to Arm(s): Suvorexant | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A